Sign In
Buy PTN
$11.77
+0.0500 (+0.427%)
At Close: Jun 22, 2026
Clinical Remission: Achieved in 33% of PL8177-treated patients versus 0% on placebo after eight weeks of treatment. Clinical Response (statistically significant): Demonstrated in 78% of PL8177-treated
Palatin's Oral MC4R Agonist PL7737 Receives FDA Orphan Drug Designation for Obesity Due to Leptin Receptor Deficiency
07:30am, Tuesday, 25'th Mar 2025
Initiated IND-enabling toxicology program IND submission planned for 4Q25; Clinical data expected in 1H26 CRANBURY, N.J. , March 25, 2025 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PT
Palatin Technologies, Inc. (PTN) Q2 2025 Earnings Call Transcript
05:41am, Saturday, 15'th Feb 2025
Palatin Technologies, Inc. (NYSE:PTN ) Q2 2025 Earnings Conference Call February 13, 2024 11:00 AM ET Company Participants Carl Spana - CEO and President Stephen Wills - CFO, COO, Treasurer and Secret
Palatin Reports Second Quarter Fiscal Year 2025 Financial Results and Provides Business Update
07:30am, Thursday, 13'th Feb 2025
Phase 2 obesity co-administration study with MC4R agonist bremelanotide plus GLP-1/GIP dual agonist tirzepatide Database lock completed Topline data readout expected later this month Novel 'next gener
Palatin to Report Second Quarter Fiscal Year 2025 Results; Teleconference and Webcast to be held on February 13, 2025
04:00pm, Monday, 10'th Feb 2025
CRANBURY, N.J. , Feb. 10, 2025 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) will announce its second quarter fiscal year 2025 operating results on Thursday, February 13, 2025, befor
Palatin Announces $4.7 Million Registered Direct Offering and Concurrent Private Placement
08:00am, Friday, 07'th Feb 2025
CRANBURY, N.J. , Feb. 7, 2025 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) ("Palatin" or the "Company"), a biopharmaceutical company developing first-in-class medicines based on mo
Palatin Completes Phase 2 Obesity Study With MC4R Bremelanotide Plus GLP-1/GIP Tirzepatide
07:30am, Thursday, 06'th Feb 2025
Last Patient / Last Visit Completed Topline Data Readout Expected Later This Quarter CRANBURY, N.J. , Feb. 6, 2025 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical
Palatin Provides Update on Anticipated 2025 Corporate Milestones
07:30am, Tuesday, 28'th Jan 2025
Obesity programs: Phase 2 BMT-801 clinical study with MC4R agonist bremelanotide plus GLP-1/GIP dual agonist tirzepatide Topline results expected 1Q calendar year 2025 General obesity, weight loss ma
Palatin Announces Positive Phase IIb BREAKOUT Study Results in Patients with Type 2 Diabetic Nephropathy
07:30am, Thursday, 19'th Dec 2024
Open label study designed to evaluate the safety, tolerability, and efficacy of bremelanotide in patients with Type 2 diabetic nephropathy Demonstrated efficacy at 6 months 71% percent of patients ach
Palatin Announces Exercise of Warrants for Approximately $3.4 Million Gross Proceeds
07:30am, Monday, 16'th Dec 2024
CRANBURY, N.J. , Dec. 16, 2024 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) ("Palatin" or the "Company"), a biopharmaceutical company developing first-in-class medicines based on m
Oral PL8177 may provide a safe, effective, and tolerable treatment option for ulcerative colitis patients prior to immunosuppressive therapies and steroid treatments, which have significant safety and
Palatin Technologies, Inc. (PTN) Q1 2025 Earnings Conference Call Transcript
12:49pm, Thursday, 14'th Nov 2024
Palatin Technologies, Inc. (NYSE:PTN ) Q1 2025 Earnings Conference Call November 14, 2024 11:00 AM ET Company Participants Carl Spana - CEO and President Stephen Wills - CFO, COO, Treasurer and Secret
Palatin Reports First Quarter Fiscal Year 2025 Operating/Financial Results
07:30am, Thursday, 14'th Nov 2024
Obesity programs: Core focus on obesity includes exploratory co-administration BMT-801 study and two novel development drug candidates Phase 2 BMT-801 clinical study with MC4R agonist bremelanotide pl
Palatin to Report First Quarter Fiscal Year 2025 Results; Teleconference and Webcast to be held on November 14, 2024
09:57am, Friday, 08'th Nov 2024
CRANBURY, N.J. , Nov. 8, 2024 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) will announce its first quarter fiscal year 2025 operating results on Thursday, November 14, 2024, before
Palatin Presents Data on Novel Melanocortin 4 Receptor Selective Oral Small Molecule PL7737 Obesity Program at ObesityWeek® 2024
07:30am, Monday, 04'th Nov 2024
Oral PL7737 significantly decreased food intake and body weight Oral small molecule melanocortin 4 agonist (MC4R) could address unmet needs and challenges of current obesity treatments Multiple clinic
